Clinuvel Pharmaceuticals Limited (ASX:CUV) is a global biopharmaceuticals company with a focus on developing and delivering treatments for patients with a range of severe genetic and skin disorders. Clinuvel’s main product is called SCENESSE, which it develops and self-distributes.
The Clinuvel Pharmaceuticals Limited (ASX:CUV) share price was trading 5% lower today. Over the past month, shares of Clinuvel Pharmaceuticals Limited are down 5%.
The Clinuvel Pharmaceuticals Limited (ASX:CUV) share price had lifted 4.8% higher today as the broader S&P/ASX 200 (INDEXASX:XJO) was mostly flat.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.18% at lunch.
Clinuvel Pharmaceuticals Limited (ASX:CUV) shares are up nearly 90% year-to-date and 200% over the last 12 months. Is it too late to buy?
One of the changes in the S&P Dow Jones Indices rebalancing is that Afterpay Touch Group Ltd (ASX:APT) is entering the ASX 100.
